Short Bowel Syndrome Market

LAS VEGAS, NEVADA, UNITED STATES, March 31, 2024 /EINPresswire.com/ -- DelveInsight’s “Short Bowel Syndrome Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of Short Bowel Syndrome, historical and forecasted epidemiology as well as Short Bowel Syndrome market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Key Takeaways from the Short Bowel Syndrome Market Research Report
• Short Bowel Syndrome affects females more than males.
• Ironwood entered into definitive agreement to acquire VectivBio. With this deal, the company's portfolio now includes apraglutide, asynthetic GLP-2 analogue of the third generation being studied for SBS with intestinal failure (SBS-IF). The drug received orphan drug designation for treatment of adult patients with SBS-IF.
• The leading Short Bowel Syndrome Companies working in the market include VectivBio, Zealand Pharma, 9 Meters Biopharma, Hanmi Pharmaceutical, Adocia, PhaseBio Pharmaceuticals, Surrozen, NorthSea Therapeutics, and others.
• Promising Short bowel syndrome Pipeline Therapies in the various stages of development include Apraglutide, Glepaglutide, HM15912, and others.
• January 2023: VectivBio AG announced a study of Phase 3 clinical trials for Apraglutide. The primary objective of the trial is to assess long-term safety and tolerability of apraglutide in subjects with SBS-IF.
• January 2023: Hanmi Pharmaceutical Company Limited announced a study of Phase 2 clinical trials for HM15912 Active. This is a randomized, double-blind, placebo-controlled, proof-of-concept (PoC), Phase 2 study to assess the safety, PK, and PD of SC administration of HM15912 in adult subjects with SBS-associated intestinal failure (SBS-IF).

Discover which therapies are expected to grab the Short Bowel Syndrome Market Share @ Short Bowel Syndrome Market Outlook

Short Bowel Syndrome Overview
Short bowel syndrome (SBS) is a complex disease that occurs due to the physical loss or the loss of function of a portion of the small and/or large intestine. SBS is generally broken down into individuals in whom the disorder is acquired during life and new borns in which the disorder is present at birth (congenital). Acquired short bowel syndrome is more common than the congenital form of the disorder.

Short Bowel Syndrome Epidemiology Segmentation in the 7MM
• Prevalence of Home Parenteral Nutrition (HPN) Use
• Short Bowel Syndrome Diagnosed Prevalent Cases
• Age-Specific Cases of Short Bowel Syndrome
• Gender-Specific Cases of Short Bowel Syndrome
• Etiology-Specific Cases of Short Bowel Syndrome

Download the report to understand which factors are driving Short Bowel Syndrome epidemiology trends @ Short Bowel Syndrome Epidemiological Insights

Short Bowel Syndrome Treatment Landscape
The treatment of SBS is directed toward the specific symptoms that are apparent in each individual. It includes nutritional support, medications, surgery, and intestinal transplant. The specific therapeutic procedures and interventions for individuals with a short bowel syndrome might vary, depending upon numerous factors, including the specific symptoms, the site and extent of the affected portion of the small intestine, whether the colon is involved, an individual’s age and overall health, tolerance of certain medications or procedures, personal preference, and other factors.

Short Bowel Syndrome Market Insights
Despite advances in management in recent decades, SBS continues to carry a high morbidity and mortality burden. Although potentially lifesaving, PN/IV is costly, invasive, and associated with numerous complications and deleterious effects on health and quality of life. Surgical interventions, especially intestinal transplantation, are costly and are associated with substantial morbidity and high mortality. New therapies, which show promise in promoting intestinal rehabilitation and reducing dependence on PN/IV therapy, are the subject of active research. GLP-2 agonists, and more recently, GLP-1agonists have been used to increase nutrient and fluid absorption and partially or wholly ameliorate the use of PN in SBS patients.

Short Bowel Syndrome Emerging Therapies
• GATTEX (Teduglutide)
• ZORBTIVE (Somatropin)
• Intestinal transplant
• Symptomatic medications (proton pump inhibitors, choleretic agents, antidiarrheal agents, antisecretin agents, etc.)
• Surgery

Short Bowel Syndrome Market Dynamics
The short bowel syndrome market dynamics are anticipated to change in the coming years. Recent clinical trials show that in the treatment of short bowel syndrome, both GLP-2 and the long-acting GLP-2 analog effectively enhance fluid absorption, leading to significant reductions in parenteral nutrition requirements. Current SBS treatments not only relieve symptoms but also enhance patients’ quality of life. Multiple organizations are actively engaged in providing information and raising awareness about such disorders. The limited treatment options for short bowel syndrome present an opportunity for the development of new therapies, creating a platform for growth in the market of short bowel syndrome.

Short Bowel Syndrome Drugs Uptake
Glepaglutide, which is being developed by Zealand Pharma, is under Phase III stage of clinical development for the treatment of patients with SBS. The drug received orphan drug designation by the FDA for the treatment of SBS in October 2017. Glepaglutide is a long-acting GLP-2 analog with an effective half-life of ~50 h. The drug is given as once- or twice-weekly dosing via autoinjector. Zealand anticipates submitting an NDA to the FDA for glepaglutide.

Apraglutide by VectivBio, is a next-generation, synthetic GLP-2 analog rationally designed with the potential to offer an improved safety and efficacy profile relative to other agents in its class. In December 2018, the FDA granted orphan drug designation to apraglutide for the treatment of SBS. VectivBio is pursuing a novel clinical strategy across a range of applications for apraglutide, beginning with STARS, a global Phase III program for the treatment of SBS with intestinal failure. In May 2023, Ironwood entered into definitive agreement to acquire VectivBio. With this deal, the company's portfolio now includes apraglutide, a synthetic GLP-2 analogue of the third generation being studied for SBS with intestinal failure (SBS-IF). The drug received orphan drug designation for treatment of adult patients with SBS-IF.

HM15912 by Hanmi Pharmaceutical is a long-acting GLP-2 analog chemically conjugated with constant region of human immunoglobulin via non-peptidyl flexible linker (LAPSCOVERY). It has received orphan drug designation for SBS. In nonclinical studies, remarkable intestinal growth in animal model of SBS was observed. In additional rodent model, HM15912 achieved significantly improved intestinal growth and absorption capacity after switching fromconventional daily GLP-2 therapy.

Scope of the Short Bowel Syndrome Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Short Bowel Syndrome Companies- VectivBio, Zealand Pharma, 9 Meters Biopharma, Hanmi Pharmaceutical, Adocia, PhaseBio Pharmaceuticals, Surrozen, NorthSea Therapeutics, and others.
• Short bowel syndrome Pipeline Therapies- Apraglutide, Glepaglutide, HM15912, and others.
• Short Bowel Syndrome Market Dynamics: Short Bowel Syndrome Market Drivers and Barriers

Discover more about Short Bowel Syndrome Drugs in development @ Short Bowel Syndrome Ongoing Clinical Trials Analysis

Table of content
1. Key Insights
2. Report Introduction
3. Short Bowel Syndrome Market Overview at a Glance
4. Executive Summary
5. Key Events
6. Short Bowel Syndrome Epidemiology and Market Methodology
7. Short Bowel Syndrome Disease Background and Overview
8. Short Bowel Syndrome Treatment
9. Short Bowel Syndrome Epidemiology and Patient Population
10. Short Bowel Syndrome Patient Journey
11. Short Bowel Syndrome Marketed Product
12. Short Bowel Syndrome Emerging Drugs
13. Short Bowel Syndrome: 7 Major Market Analysis
14. Short Bowel Syndrome Unmet Needs
15. Short Bowel Syndrome SWOT Analysis
16. Short Bowel Syndrome KOL Views
17. Short Bowel Syndrome Market Access and Reimbursement
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Yash Bhardwaj
DelveInsight
+91 9650213330
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.